Laboratory for Medical Research 8, Anesthesiology Department, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Laboratory for Medical Research 12, Division of Nephrology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Shock. 2023 Sep 1;60(3):469-477. doi: 10.1097/SHK.0000000000002191. Epub 2023 Jul 29.
Background: Approximately 50% of patients with sepsis develop acute kidney injury (AKI), which is predictive of poor outcomes, with mortality rates of up to 70%. The endothelium is a major target for treatments aimed at preventing the complications of sepsis. We hypothesized that human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) could attenuate tubular and endothelial injury in a porcine model of sepsis-induced AKI. Methods: Anesthetized pigs were induced to fecal peritonitis, resulting in septic shock, and were randomized to treatment with fluids, vasopressors, and antibiotics (sepsis group; n = 11) or to that same treatment plus infusion of 1 × 10 6 cells/kg of hUC-MSCs (sepsis+MSC group; n = 11). Results: At 24 h after sepsis induction, changes in serum creatinine and mean arterial pressure were comparable between the two groups, as was mortality. However, the sepsis+MSC group showed some significant differences in comparison with the sepsis group: lower fractional excretions of sodium and potassium; greater epithelial sodium channel protein expression; and lower protein expression of the Na-K-2Cl cotransporter and aquaporin 2 in the renal medulla. Expression of P-selectin, thrombomodulin, and vascular endothelial growth factor was significantly lower in the sepsis+MSC group than in the sepsis group, whereas that of Toll-like receptor 4 (TLR4) and nuclear factor-kappa B (NF-κB) was lower in the former. Conclusion: Treatment with hUC-MSCs seems to protect endothelial and tubular cells in sepsis-induced AKI, possibly via the TLR4/NF-κB signaling pathway. Therefore, it might be an effective treatment for sepsis-induced AKI.
约 50%的脓毒症患者会发生急性肾损伤(AKI),这是预后不良的预测指标,死亡率高达 70%。内皮细胞是预防脓毒症并发症的治疗的主要靶点。我们假设人脐带间充质干细胞(hUC-MSCs)可减轻脓毒症诱导的 AKI 猪模型中的肾小管和内皮损伤。
麻醉猪诱发粪便性腹膜炎,导致脓毒性休克,并随机分为液体、血管加压素和抗生素治疗(脓毒症组;n = 11)或相同治疗加 1 × 10 6 个细胞/kg hUC-MSCs 输注(脓毒症+MSC 组;n = 11)。
在脓毒症诱导后 24 小时,两组血清肌酐和平均动脉压的变化、死亡率无差异。然而,与脓毒症组相比,脓毒症+MSC 组有一些显著差异:钠和钾的分数排泄较低;上皮钠通道蛋白表达增加;肾髓质的 Na-K-2Cl 共转运蛋白和水通道蛋白 2 的蛋白表达降低。P-选择素、血栓调节蛋白和血管内皮生长因子在脓毒症+MSC 组的表达明显低于脓毒症组,而 Toll 样受体 4(TLR4)和核因子-kappa B(NF-κB)在前者中的表达较低。
hUC-MSCs 治疗似乎可保护脓毒症诱导的 AKI 中的内皮细胞和肾小管细胞,可能通过 TLR4/NF-κB 信号通路。因此,它可能是脓毒症诱导的 AKI 的有效治疗方法。